Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Hexanoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.76 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.73 |
| ▸ | PPARG | P37231 | 7/20 | 0.73 |
| ▸ | PPARD | Q03181 | 7/20 | 0.73 |
| ▸ | PPARA | Q07869 | 7/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.73 |
| ▸ | TSHR | P16473 | 4/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.73 |
| ▸ | FABP4 | P15090 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | TLR2 | O60603 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.73 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | PDE4A | P27815 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stearic Acid SCHEMBL1143367 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Dodecanoate SCHEMBL10885528 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Decanoic Acid SCHEMBL19253047 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Octanoic Acid SCHEMBL28380328 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Palmitic Acid SCHEMBL9442061 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Myristic Acid SCHEMBL27470469 | 0.98 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Stearic Acid SCHEMBL23925106 | 0.96 | GPR84 (0.74) | AKR1B1GPR84PPARGPPARDPPARA | |
| Valeric Acid SCHEMBL31741355 | 0.93 | AKR1B1 (0.64) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexanoate SCHEMBL13836524 | 0.90 | AKR1B1 (0.84) | AKR1B1GPR84PPARGPPARDPPARA | |
| Dodecanoate SCHEMBL6130627 | 0.88 | GPR84 (0.85) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-109369635-B | Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition | 赛克里翁治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-111836812-A | Crystalline forms of sGC stimulators | 塞科里昂医疗股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-107021951-B | sGC stimulators | 赛克里翁治疗有限公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-111712247-A | sGC stimulators | 塞科里昂医疗股份有限公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-107223125-B | SGC stimulant | 赛科理音医疗有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110267658-A | Treatment of CNS disorders with sGC stimulators | 塞科里昂医疗股份有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110267949-A | SGC stimulant | 塞科里昂医疗股份有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110016020-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109790167-A | SGC stimulators | 艾恩伍德医药品股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| CN-101453985-A | Compositions for promoting hair growth | NOVUS INT INC (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-0401248-A4 | AFFINITY MATRICES OF MODIFIED POLYSACCHARIDE SUPPORTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-5059654-A | Synthetic polymer; affinity ligand or biologically active molecule; hydrophobic compound, chromatographic separation | CUNO INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0401248-A1 | AFFINITY MATRICES OF MODIFIED POLYSACCHARIDE SUPPORTS | Cuno Incorporated (US) | 1990-12-12 | — | — | EP | disclosed |
| WO-1989007618-A1 | AFFINITY MATRICES OF MODIFIED POLYSACCHARIDE SUPPORTS | CUNO, INCORPORATED (US) | 1989-08-24 | — | — | WO | disclosed |
| US-4639513-A | CHROMATOGRAPHIC PURIFICATION | CUNO INC. (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0180766-A2 | Intravenously injectable immunoglobulin G (IgG) and method for producing the same | Cuno Incorporated (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | AKR1B1 3298/4885GPR84 718/4885PPARG 1589/4885 |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | AKR1B1 690/4885GPR84 3639/4885PPARG 104/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | AKR1B1 690/4885GPR84 3639/4885PPARG 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.